Daiichi Sankyo Korea and Daewoong announce co-promotion agreement of ‘Lixiana’

Published: 2015-12-24 13:47:39

Updated: 2015-12-24 13:48:12

Daiichi Sankyo Korea(CEO Dae-joong Kim) and Daewoong Pharmaceutical(CEO Jong-ok Lee) announced a co-promotion agreement of ‘Lixiana,’ an oral anticoagulant, on the 21^st.

Daiichi Sankyo Korea and Daewoong Pharmaceutical are planning to cooperate on sales and marketing, and launch 3 different volumes of the drug, 60mg, 30mg and 15mg.

Lixiana, developed by Daiichi Sankyo, is an oral anticoagulan...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Daiichi Sankyo Korea and Daewoong announce co-promotion agreement of ‘Lixiana’

Daiichi Sankyo Korea(CEO Dae-joong Kim) and Daewoong Pharmaceutical(CEO Jong-ok Lee) announced a co-promotion agreement of ‘Lixiana,’ an oral anticoagulant, on the 21st.

Fees

Daiichi Sankyo Korea(CEO Dae-joong Kim) and Daewoong Pharmaceutical(CEO Jong-ok Lee) announced a co-promotion agreement of ‘Lixiana,’ an oral anticoagulant, on the 21^st.